| Latest | F'cast | |
|---|---|---|
| Div Yield | 4.2% | 0.0% |
| Div Cover | 2.7 | 2.8 |
| Op Mrgn | 16.2% | 22.3% |
| ROCE | 17.5% |
| Latest | F'cast | |
|---|---|---|
| P/E | 8.8 | 9.2 |
| PEG | 5.0 | 1.0 |
| Pr/Revenue | 1.3 | 1.0 |
| Pr/Book | 1.6 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 7.1% | -100.0% |
| PBT | 14.1% | -100.0% |
| EPS | 1.8% | 10.8% |
| DPS | 5.0% | n/a |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 2,553.00 | 544.00 | 194.80¢ | 15.2 | 1.2 | +13% | 54.00¢ | 1.8% |
| 31-Dec-22 | 2,517.00 | 233.00 | 181.00¢ | 11.4 | n/a | -7% | 56.00¢ | 2.7% |
| 31-Dec-23 | 2,875.00 | 281.00 | 223.00¢ | 10.7 | 0.5 | +23% | 72.00¢ | 3.0% |
| 31-Dec-24 | 3,127.00 | 455.00 | 224.00¢ | 11.9 | n/a | 0% | 80.00¢ | 3.0% |
| 31-Dec-25 | 3,349.00 | 519.00 | 228.00¢ | 9.1 | 4.5 | +2% | 84.00¢ | 4.1% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Holding(s) in Company | 24-Jul-2026 | 11:25 | RNS |
| Holding(s) in Company | 23-Jul-2026 | 15:21 | RNS |
| Transaction in Own Shares | 20-Jul-2026 | 09:22 | RNS |
| Hikma boosts injectables business with $300m deal | 29-May-2014 | Telegraph |
| MARKET REPORT: Shares jump as Hikma Pharmaceutic... | 08-May-2014 | Daily Mail |
| Hikma prepares return to Libya | 26-Aug-2011 | The Independent |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 1,582.00p |
| Change Today | 29.00p |
| % Change | 1.87 % |
| 52 Week High | 2,028.00 |
| 52 Week Low | 1,191.00 |
| Volume | 530,021 |
| Shares Issued | 211.20m |
| Market Cap | £3,341.26m |
| Beta | 0.00 |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Final | Interim | |
| Ex-Div | 19-Mar-26 | 14-Aug-25 |
| Paid | 30-Apr-26 | 18-Sep-25 |
| Amount | 48.00¢ | 36.00¢ |
| Time | Volume / Share Price |
| 16:49 | 126 @ 1,582.00p |
| 16:38 | 109,895 @ 1,573.15p |
| 16:35 | 143,308 @ 1,582.00p |
| 16:35 | 483 @ 1,582.00p |
| 16:35 | 605 @ 1,582.00p |
| CEO | Said Darwazah |
| Chair | Victoria Hull |
You are here: research